Will GDUFA, BSUFA Sunset If Sequestration Rises?
Executive Summary
The new user fee programs for generic and biosimilar products may need to be authorized retroactive to 2011 in order to be collected should federal budget sequestration take place.
You may also be interested in...
As GDUFA Launch Nears, Is Sitting In The Backlog More Appealing?
More submissions are going into the generic drug backlog, likely because the backlog fee is expected to be less than half the GDUFA application fee.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.